Journal
MOLECULAR NEUROBIOLOGY
Volume 54, Issue 8, Pages 6507-6522Publisher
HUMANA PRESS INC
DOI: 10.1007/s12035-016-0169-8
Keywords
Amyloidogenic protein expression; Insulin receptor dysfunction; Glial activation; Intranasal insulin`; post synaptic neurotoxicity
Categories
Funding
- DBT [BT/PR4012/MED/30/672/201]
- SRF
Ask authors/readers for more resources
Alzheimer's disease (AD) is associated with reduced insulin level and impairment of insulin receptor (IR) signaling in the brain, which correlates to amyloid pathology, neuroinflammation, and synaptic neurotoxicity. Clinical studies show that intranasal insulin improves memory in AD patients without peripheral hypoglycemia. However, neuroprotective molecular mechanism of the beneficial effect of intranasal insulin in AD pathology is unexplored. Therefore, we investigated the role of intranasal insulin on intracerebroventricular (ICV) streptozotocin (STZ)-induced memory impairment in rats as evaluated in the Morris water maze test. STZ (ICV) treated rats had shown memory impairment along with a significant decrease in IR signaling molecules (IR, pIRS-1, pAkt, and pGSK-3 alpha/beta expression) and IDE expression in both hippocampus and cerebral cortex. Intranasal insulin delivery prevented these changes. Moreover, intranasal insulin was found to inhibit significantly glial cell activation (GFAP and Iba-1 expression), neuroinflammation (COX-2 expression, NF kappa B translocation, TNF-alpha, and IL-10 level) and amyloidogenic protein expression (BACE-1 and A beta(1-42) expression) in STZ (ICV)-injected rats. STZ (ICV)-induced caspase activation and postsynaptic neurotoxicity were also prevented by treatment with intranasal insulin. Our findings reveal that insulin has the neuroprotective effect and clearly signifies the potential use of intranasal insulin delivery for the treatment of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available